

26 June 2014
EMA/HMPC/355484/2014
Procedure Management and Business Support Division

## Committee on Herbal Medicinal Products (HMPC)

Agenda of the 30 June-1 July 2014 meeting

30 June 2014, 14:00 – 19:00, room 3A, *plenary* 1 July 2014, 08:30 – 12:30, room 3A, *plenary* (Visit to 30 Churchill place on 1 July 2014, 19:00)

Chair: Werner Knöss

## Health & Safety Information

In accordance with Agency policy, delegates are to be shown a slide show with health and safety and emergency information and procedures. This is to be displayed at the start of this meeting using the Crestron system as delegates are entering the meeting room. In addition, the meeting secretariat is to draw the delegates' attention to the slideshow and point out the nearest fire exit(s), which are marked where the room has two or more exits. Should there be an evacuation during the meeting staff will quide delegates out of the building via the nearest fire exit.

## Declaration of conflict of interests

In accordance with the Agency's Policy and Procedure on the handling of conflicts of interests, participants in this meeting are asked to declare any conflict of interests on the matters for discussion (in particular any changes, omissions or errors to the already declared interests). Discussions, deliberations and voting will take place in full respect of the restricted involvement of Scientific Committee members and, where relevant, experts attending the plenary meeting, as announced by the Scientific Committee secretariat at the start of the meeting.

 Draft annex to the minutes for the June/July 2014 HMPC meeting, documenting anticipated restriction on involvement in relation to agenda topics and declarations of interest from members and alternates (EMA/HMPC/382257/2014)

## · Note on access to documents

Some documents mentioned in the agenda/minutes cannot be released at present within the framework of Regulation (EC) No 1049/2001 on access to documents because they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).



- Change introduced after 2370		
I. Indus directions		
I. Introduction  I.1 Agenda, minutes		
1.1 Agenda, minutes		
I.1.1 Agenda of 30 June-1 July 2014 HMPC	Tabled	
meeting		
- timetable, for order of topics		
For adoption 1.1.2 Minutes of 5-6 May 2014 HMPC	Tabled	
meeting	Tabled	
For adoption		
I.2 Legislation and regulatory affairs		
I.2.1 Validation of the BSS - assessment of	Report: HMPC Chair	
reliability and implications for specific monographs		
- draft assessment report - letter dated 18 Dec 2013	Tabled	
- response with attachments received on 30 April		
2014		
- list of additional data/literature		
- positions from Rapporteurs		
For discussion		
1.3 Questions raised by HMPC members		
I.3.1 New QRD template for THMPs in mutual	Report: P. Claeson	
recognition and decentralised procedures		
- email For discussion	Tabled	
I.4 Questions raised by companies		
I.5 Referral procedures		
II.Co-ordination issues		
II.1 General co-ordination issues		
II.2 Co-ordination with CHMP		
II.3 Co-ordination with SAWP		
II.4 Co-ordination with SWP		
II. 4.1 Assessment of estragely and alkanyl	Tabled	
II.4.1 Assessment of estragole and alkenyl benzenes	Tabled	
- draft discussion paper		
- status report		
- presentation		
- letter to SWP Chair		
- HMPC PS on the use of HMPC cont estragole		
For discussion		

	_			
II.4.2 Revision on Public Statement on the use of herbal medicinal products containing pulegone and menthofuran	Tabled			
<ul> <li>discussion paper toxicological assessment</li> <li>comments received during May written procedure</li> <li>draft revised public statement</li> <li>letter to SWP Chair</li> <li>presentation</li> <li>menthae piperitae aetheroleum - monograph</li> </ul>				
For discussion				
II.5 Co-ordination with PDCO				
II.6 Co-ordination with PRAC				
II.7 Co-ordination with PCWP				
II.8 Co-ordination with HCPWP				
II.9 Co-ordination with Medical Writers				
II.10 Co-ordination with COMP				
II.11 Co-ordination with CMDh				
II.12 Co-ordination with Eur. Com.	II.12 Co-ordination with Eur. Com.			
II.13 Co-ordination with EFSA				
III. Organisational matters				
III.1 Organisational Matters Drafting Group				
III.1.1 Virtual ORGAM DG meeting to be held on 13 May 2014	Report: ORGAM DG Chair			
- meeting report  For information	Meeting 10 June postponed			
roi illioittation	Tabled			
III.2 Working methodology				
III.2.2 Nomination of co-opted members - procedure for nomination co-opted members for HMPC, 12 Nov 04 - Overview of expertise available in the HMPC For discussion	Report: HMPC Chair  Tabled			
III.2.3 Organisation of an assessors' training in 2014 for 20 participants - agenda For discussion	Report: HMPC Chair Supported by: R. Länger, H. Neef, I. Chinou			
III.2.4 Move to new EMA offices in July 2014 - presentation For information				

	T
III.2.5 Survey 'Uptake of traditional use	Tabled
registration scheme and implementation of the	
provisions of Directive 2004/24/EC in EU Member	
States' (2013 data)	
- status report	
For discussion	
III.2.6 HMPC work plan and input for EMA work	EMA: Roberto De Lisa
programme 2015	
- presentation	Tabled
- current work programmes HMPC, MLWP, Q DG,	Tabled
ORGAM DG	
For discussion	
IV. Quality	<u> </u>
IV.1 Quality Drafting Group	
IV.1.1 Meeting report from Q DG meeting held	Report: Q DG Chair
on 18 June 2014	
For adoption	
,	Tabled
IV.1.2 O&A on herbal substances that do not	For inclusion into Quality Q and A document
contain an assay in the Ph.Eur. monograph.	(EMEA/HMPC/41500/2010)
For adoption	(EME/V11VIII 0/ 41300/2010)
	Tabled
IV 1.2 ORA on borbal propagation that do not	
IV.1.3 Q&A on herbal preparation that do not	For inclusion into Quality Q and A document
contain an assay in the Ph.Eur. monograph.	(EMEA/HMPC/41500/2010)
For adoption	
	Tabled
IV.1.4 Q&A on declaration of DER and extraction	For inclusion into Quality Q and A document
solvent in case of fresh herbal substances	(EMEA/HMPC/41500/2010)
For adoption	
	Tabled
IV.1.5 Q DG comments on EDQM monograph on	Tabled
fresh herbal drugs	
For adoption	
IV.2 European Pharmacopeia	
IV.2.1 Report from EDQM Expert Group 13A	EDQM: M. Bald
meeting held on 2-3 June 2014	HMPC Observer: I. Chinou
- group 13A summary of decisions	
For discussion	Tabled
IV.2.2 Report from EDQM Expert Group TCM	EDQM: M. Bald
meeting held on 5-6 June 2014	HMPC Observer: R. Länger
- group TCM summary of decisions	
For discussion	Tabled
IV.2.3 Priority of herbal substances with a need of	Tabled
•	Tableu
Ph. Eur. Monographs for submission to EDQM	
- priority list (EMA/HMPC/328288/2014) submitted	
28/05/14	
For information	

IV.2.4 Request by EDQM on isomenthone For discussion	Tabled		
V. Safety & efficacy			
V.1 Report on MLWP activities			
V 1 1 Depart on progress ashiound	Danart, MI WD Chair		
V.1.1 Report on progress achieved	Report: MLWP Chair		
Overview of status of MLWP assessment work			
For discussion			
V.1.2 Appointment for Rapporteurs and Peer-			
reviewer			
Herbal substance	Rapporteur	Peer-reviewer	
Arctii radix (M)			
Boldi folium (M)			
Caryophylii flos (PS)			
Caryophylii floris aetheroleum (M)			
Centaurii herba (M)			
Curcumae longae rhizoma (M)			
Equiseti herba (M)			
Hamamelidis folium et cortex aut ramunculus destillatum	(M+LE)		
Hamamelidis cortex (M)			
Hamamelidis folium (M)			
Harpagophyti radix (M)			
Hippocastani cortex (M)			
Hippocastani semen (M)			
Orthosiphonis folium (M)			
Leonuri cardiacae herba (M)			
Mate folium (M)			
Polypodii rhizoma (M)			
Salicis cortex (M)			
Sideritis herba			
Taraxaci radix cum herba (M)			
Taraxaci folium (M)			
Thymi aetheroleum (M + LE)			
Trigonellae foenugraeci semen (M)			
Vitis viniferae folium (M + LE)			
Myrtilli fructus, myrtilli recens, myrtilli fructus siccus (M)			
V.2 Community list entries transmitted to Euro	pean Commission		
V.3 Community herbal monographs for public of	consultation/final adoption	n after systematic	
review/revision			
V.4 Community herbal monographs (post finalisation)			
V.5 Community herbal monographs, Community list entries and public statements for adoption after public consultation			
V.5.1 Monograph on Rosae flos (and supporting	7.5.1 Monograph on Rosae flos (and supporting Tabled		
documents: AR, LoR, references 0/32)			
For adoption			
·			
V.6 Community herbal monographs, Community list entries and public statements for adoption for release for public consultation			

Tabled		
Tabled		
V.7 Community herbal monographs, Community list entries and public statements for discussion		
<u>ojects</u>		
vith non-EU regulatory authorities		
Tabled		
http://www.ema.europa.eu/docs/en_GB/document_librar y/Committee_meeting_report/2014/05/WC500167583.p df		
Tabled		
•		
Tabled		
Tabled Tabled		

VI.3.7 Inventory of herbal substances for assessment work – alphabetical order		
VI.3.8 Common names of herbal substances in all	Tabled	
EU official languages		
VI.4 Any other information		
VI.4.1 Abbreviations in HMPC minutes	http://www.ema.europa.eu/docs/en_GB/document_librar	
	y/Other/2013/11/WC500155666.pdf	